| Characteristics |
Results |
|
Age of SSc onset mean ± SD (range), in years |
44.3 ± 11.4 (21-74)
|
|
Disease duration at ILD diagnosis mean ± SD (range), in years |
4.6 ± 4.6 (0-23)
|
| Gender |
| Female: Male, n (%)
|
26 (68): 12 (32) |
| Race |
| Caucasian, n (%)
|
28 (74) |
| African American, n (%)
|
7(18) |
| Other, n (%)
|
3 (8) |
| Subtype |
| lcSSc: dcSSc, n (%)
|
16 (42): 22 (58) |
| Autoantibody Status |
| positive ACA, n
|
1 |
| positive anti-TPO, n
|
18 |
|
Baseline % predicted FVC, mean ± SD (range)
|
63.3 ± 12.4 (39.4-95.5)
|
|
Baseline % predicted DLco, mean ± SD (range)
|
52.6 ± 16.4 (26.2-102.1)
|
|
Follow-up period mean ± SD (range), in years |
5.1 ± 2.1 (2.3-10.8)
|
|
Duration of CYC therapy mean ± SD (range), in months |
20.3 ± 13.6 (6 months-6.7 years)
|
Legend: ACA- anti-centromere antibody: 3 missing ; Anti-TPO-anti-topoisomerase antibody: 2 missing; SSc- systemicscleroderma; CYC-cyclophosphamide; FVC- forced vital capacity; DLco-single-breath carbon monoxide diffusing capacity; lcSSc- limited cutaneous scleroderma; dcSSc-diffuse cutaneous scleroderma.